Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2382 - The combination of trifluridine/tipiracil and oxaliplatin induces immunogenic cell death in microsatellite stable colorectal cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Immunology

Tumour Site

Colon and Rectal Cancer

Presenters

Francois Ghiringhelli

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

F. Ghiringhelli1, E. Limagne2, M. Thibaudin2, L. Nuttin2, A. Spill2, V. Derangere2, V. Cattan3, E. Peranzoni4, N. Amellal3

Author affiliations

  • 1 Medical Oncology Unit, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 2 Plateform Of Cancer biology, Centre Georges-François Leclerc, 21000 - Dijon/FR
  • 3 Servier Oncology, Instut de recherches internationales Servier, 92284 - Suresnes/FR
  • 4 Servier Oncology, Instut de recherches Servier, 78290 - Croissy/FR
More

Resources

Abstract 2382

Background

Patients with microsatellite-stable (MSS) colorectal cancer have limited clinical benefit with PD-1 blockade [1, 2]. These tumors are poorly immunogenic and highly infiltrated by immunosuppressive populations [3]. In this context, identification of drug combinations both inducing immunogenicity and modulating tolerogenicity is crucial for the sensitization of MSS colorectal cancer to immune-checkpoint inhibitors. The aim of this study was to evaluate the immunological properties of the trifluridine/tipiracil and oxaliplatin combination in the murine MSS colorectal cancer CT26 model.

Methods

Immunogenic cell death was evaluated both in vitro and in vivo (HMGB1/ATP release, calreticulin and EIF2α endoplasmic reticulum stress marker). Both antitumor CD8 (IFNγ, Granzyme B, PD-1) and tolerogenic (including Treg, polymorphonuclear-granulocytic/monocytic myeloid-derived suppressor cells and tumor-associated macrophages [TAM]) responses were analyzed by immunochemistry and flow cytometry.

Results

Combined therapy induced all immunogenic cell death markers in vitro. In tumor tissue, HMGB1 nuclear delocalization and EIF2α phosphorylation were significantly increased after trifluridine/tipiracil and oxaliplatin exposure as compared to each single agent; no effect was seen with the single agents. These immunogenic signals allow the recruitment of PD-1+ CD8 cells with high capacity for production of IFNγ, TNFα and granzyme B production capacities. Furthermore, the trifluridine/tipiracil and oxaliplatin combination was seen to markedly deplete TAM, in particular TAM2.

Conclusions

The trifluridine/tipiracil and oxaliplatin combination induces immunogenic cell death and antitumor CD8 activation as well as depletion of immunosuppressive TAM2 in MSS colorectal cancer. This chemotherapy combination could therefore be considered as a potential new therapeutic option for immune checkpoint inhibitor sensitization in MSS colorectal cancer. 1. Le DT, Uram JN, Wang H, et al. N Engl J Med. 2015;372(26):2509-20. 2. Lochhead P, Kuchiba A, Imamura Y, et al. J Natl Cancer Inst. 2013;105(15):1151-6. 3. De Smedt L, Lemahieu J, Palmans S, et al. Br J Cancer. 2015;113(3):500-9.

Clinical trial identification

Legal entity responsible for the study

Servier and CGFL.

Funding

Servier.

Editorial Acknowledgement

Disclosure

F. Ghiringhelli: Consultant: AstraZeneca, Servier, Roche, BMS, Enterome, Sanofi. V. Cattan, E. Peranzoni, N. Amellal: Employee of Servier. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.